Claims for Patent: 10,682,351

Summary for Patent: 10,682,351

Title:	Methods of administering elagolix
Abstract:	The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
Inventor(s):	Goss; Sandra L. (Wadsworth, IL), Klein; Cheri E. (Northbrook, IL), Ng; Juki Wing-Keung (Highland Park, IL), Salem; Ahmed (Libertyville, IL)
Assignee:	ABBVIE INC. (North Chicago, IL)
Application Number:	16/722,741
Patent Claims:	1. A method for treating endometriosis in a patient, the method comprising: orally administering to the patient once daily 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-ben- zyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino- )-butyric acid as a sodium salt (elagolix), wherein the sodium salt is administered in an amount equivalent to 150 mg of the free acid; wherein the patient receives a once daily dose of 400 mg of ketoconazole, wherein maximum plasma concentration for elagolix is increased by 1.8 fold relative to administration of elagolix alone and wherein plasma area-under-the-curve for elagolix is increased by 2.2 fold relative to administration of elagolix alone.